The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program
PD-L1 is a critical biomarker for a breakthrough therapy for NSCLC patients. Get educated on how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx.
The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program uses in-depth content, engaging activities, and comprehensive cases to help you confidently:
- Understand the core principles of PD-L1 pathology
- Learn the process for evaluating stained images for PD-L1 expression
- Recognize confounding considerations that affect PD-L1 interpretation
- Score images for PD-L1 expression across a variety of patient samples
For in vitro diagnostic use.
PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) and melanoma tissue using EnVision FLEX visualization system on Autostainer Link 48.
Non-Small Cell Lung Cancer (NSCLC)
PD-L1 protein expression is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity.
PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab). See the KEYTRUDA® product label for expression cutoff values guiding therapy in specific clinical circumstances.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
3534 2017JUN28